More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication  RYBREVANT FASPRO™,  an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting  Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication  CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. Confirmed overall response rate was 42 percent, with more than one-third of responders achieving complete responses.